Immune Checkpoint Inhibitors in High-Grade UTUC: Organ Preservation and Improved Survival

What is it about?

This study evaluated the role of immune checkpoint inhibitors (ICIs) in patients with high-grade upper tract urothelial carcinoma (UTUC) who are managed endoscopically when nephroureterectomy (NU) is not feasible. The study found that patients who received ICIs had significantly improved overall and metastasis-free survival rates compared to those who did not receive ICIs. The study suggests that ICIs should be considered in this patient population, but more studies with larger sample sizes are needed.

Featured Image

Why is it important?

This research is important as it evaluates the role of immune checkpoint inhibitors (ICIs) in patients with high-grade upper tract urothelial carcinoma (UTUC) who are managed endoscopically when nephroureterectomy (NU) is not feasible. It demonstrates that the use of ICIs in this patient population is associated with significantly improved overall and metastasis-free survival rates, indicating that ICIs should be considered in this patient population. Key Takeaways: 1. The study evaluates the role of ICIs in patients with high-grade UTUC treated endoscopically when nephroureterectomy is not feasible. 2. The study demonstrates that the use of ICIs in this patient population is associated with significantly improved overall and metastasis-free survival rates. 3. The study highlights the importance of further assessing the efficacy of ICI therapy in treating high-grade UTUC through well-designed randomised trials.